CTOs on the Move

MarketStar

www.marketstar.com

 
Through innovative sales solutions, MarketStar (www.marketstar.com) accelerates sales from lead to recurring revenue with business-to-business (B2B) direct and indirect sales programs. Utilizing a blend of voice, digital, and field engagements, MarketStar has launched, sold and supported thousands of products and services on behalf of the biggest and most innovative companies across the globe. Founded in 1988, MarketStar pioneered the sales outsourcing industry and today has over 1,600 employees worldwide. Their global headquarters is located in Ogden, Utah.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Lars and Assoc Inc

Lars and Assoc Inc is a Hibernia, NJ-based company in the Business Services sector.

Visual Planning Corporation

Visual Planning Corporation is a Montr, QC-based company in the Business Services sector.

PRTech

PRTech is a Honolulu, HI-based company in the Business Services sector.

FlowData LLC

FlowData is a catalyst for change by guiding companies toward the adoption of cutting-edge AI capabilities. The capabilities of AI will reshape the landscape of business operations, making processes several orders of magnitude more efficient. FlowData seamlessly weaves AI into the core of your business operations, enhancing efficiency, reducing costs, and implementing robust safeguards for risk mitigation.

Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.